Cytokinetics (CYTK)

$35.14 -1.02 (-2.82%)
Market Cap 4.32B
Revenue (ttm) 18.47M
Net Income (ttm) -589.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,191.82%
Debt to Equity Ratio -0.39
Volume 1,123,200
Avg Vol 1,379,142
Day's Range N/A - N/A
Shares Out 119.43M
Stochastic %K 21%
Beta 0.64
Analysts Strong Sell
Price Target $71.37

Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 3000
Address:
350 Oyster Point Boulevard, South San Francisco, United States
dipmike
dipmike Aug. 7 at 6:59 AM
$CYTK Biotech stock breaking out from a 6-month base above $80. Volume surge confirms institutional interest. Measured move suggests $100 target. RSI(14) at 68 indicates strong momentum, but watch for potential consolidation near highs.
0 · Reply
QuantInsider
QuantInsider Aug. 5 at 8:05 PM
Big move on $CYTK Someone just grabbed 3,999 Aug 15 $45 calls at the ask That's a serious bullish play with only 10 days to go Cost them about $19,995 in premium This kind of high conviction bet signals a potential upside push Maybe even a volatility spike if CYTK rallies Keep an eye on it Could get interesting fast
1 · Reply
Quantumup
Quantumup Jul. 30 at 3:14 PM
Raymond James y'day🏁 $EWTX Strong Buy-$46 and said, "We think EWTX offers a highly attractive risk/reward skew at current prices: Upcoming Phase 2 CIRRUS-HCM Part D results in 2H25 can meaningfully de-risk EDG-7500 in oHCM." $BMY $CYTK Raymond James added, "We think results from Parts B/C are encouraging (solid efficacy, minimal LVEF % impact), suggesting a path forward with potential to avoid a REMS; the possible a-fib signal should be manageable. The opportunity in nHCM is more difficult to de-risk, but completely out of the stock, in our view."
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 27 at 8:06 PM
$VKTX should have sold at its peak like $CYTK if they wanted a buyout. Cheering on both companies and there are reasons to be bullish… But you all need to realize this is an “if they’re bought” situation, not a WHEN .
3 · Reply
bagsOfCash
bagsOfCash Jul. 25 at 2:19 PM
$CYTK institutions are accumulating, I am doing the same
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 25 at 3:56 AM
$CYTK is getting back on my radar as a potential new obstructive HCM treatment ahead of its PDUFA… I turned down an opportunity from a friend to interview there a couple of years ago and I have tracked it closely since. 📈 FYI to my fellow $TNXP $KALV $NUVB investors… also to $SLS given it may get an accelerated approval 👀 Here weeeee go! 🚀
0 · Reply
RNASequencing
RNASequencing Jul. 24 at 5:36 PM
$ABVX sold within 12 months for 100-120 a share is a my guess but m and an always difficult to predict. Seems obvious, but so was $CYTK 🤷🏼‍♂️
0 · Reply
BNBComedian
BNBComedian Jul. 23 at 2:24 AM
$CYTK better molecules better data dumb CEO
0 · Reply
bhavn0081
bhavn0081 Jul. 21 at 6:33 PM
$CYTK | BULLISH | PT $75 Entering long position here at $55. Key catalysts ahead: PDUFA Dec 26, 2025: High chance of approval. PDUFA delay was procedural (REMS), not clinical. Competitive BEAST: Aficamten shows superior data to Camzyos ($BMY). nHCM Upside: ACACIA data in H1 '26 could nearly double the addressable market. FINANCES: Fully funded through launch. Clear path to $75. M&A potential is the cherry on top.
0 · Reply
The_Fudster
The_Fudster Jul. 18 at 1:35 PM
$CYTK honestly, Dougie over at SRPT is making blum look pretty damn good right now. Think market is finally waking up that this is a quality asset at a pretty good price nearing PDUFA
0 · Reply
Latest News on CYTK
Cytokinetics Merits A Speculative Buy Rating

Jul 25, 2025, 1:23 PM EDT - 12 days ago

Cytokinetics Merits A Speculative Buy Rating

Cytokinetics to Announce Second Quarter Results On August 7, 2025

Jul 24, 2025, 4:00 PM EDT - 13 days ago

Cytokinetics to Announce Second Quarter Results On August 7, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jul 18, 2025, 4:00 PM EDT - 19 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

Jul 10, 2025, 7:30 AM EDT - 4 weeks ago

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 17, 2025, 4:00 PM EDT - 7 weeks ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

Jun 10, 2025, 7:30 AM EDT - 2 months ago

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

May 29, 2025, 4:00 PM EDT - 2 months ago

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out

May 20, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation

May 19, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 18, 2025, 10:00 AM EDT - 2 months ago

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

May 18, 2025, 8:00 AM EDT - 2 months ago

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation

May 16, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect

May 15, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

May 15, 2025, 7:30 AM EDT - 3 months ago

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation

May 14, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation

Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering

May 13, 2025, 4:06 PM EDT - 3 months ago

Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation

May 13, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation

Cytokinetics' heart disease drug meets main goal in late-stage study

May 13, 2025, 7:45 AM EDT - 3 months ago

Cytokinetics' heart disease drug meets main goal in late-stage study

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

May 13, 2025, 7:30 AM EDT - 3 months ago

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 3 months ago

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Stockholders to Connect

May 9, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Stockholders to Connect

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

May 8, 2025, 4:00 PM EDT - 3 months ago

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 8, 2025, 10:00 AM EDT - 3 months ago

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Cytokinetics to Hold Annual Meeting of Stockholders

May 7, 2025, 4:00 PM EDT - 3 months ago

Cytokinetics to Hold Annual Meeting of Stockholders

Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook

May 7, 2025, 11:29 AM EDT - 3 months ago

Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation

May 7, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation

Cytokinetics, Incorporated (CYTK) Q1 2025 Earnings Call Transcript

May 7, 2025, 1:56 AM EDT - 3 months ago

Cytokinetics, Incorporated (CYTK) Q1 2025 Earnings Call Transcript

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

May 6, 2025, 6:12 PM EDT - 3 months ago

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 4:00 PM EDT - 3 months ago

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

dipmike
dipmike Aug. 7 at 6:59 AM
$CYTK Biotech stock breaking out from a 6-month base above $80. Volume surge confirms institutional interest. Measured move suggests $100 target. RSI(14) at 68 indicates strong momentum, but watch for potential consolidation near highs.
0 · Reply
QuantInsider
QuantInsider Aug. 5 at 8:05 PM
Big move on $CYTK Someone just grabbed 3,999 Aug 15 $45 calls at the ask That's a serious bullish play with only 10 days to go Cost them about $19,995 in premium This kind of high conviction bet signals a potential upside push Maybe even a volatility spike if CYTK rallies Keep an eye on it Could get interesting fast
1 · Reply
Quantumup
Quantumup Jul. 30 at 3:14 PM
Raymond James y'day🏁 $EWTX Strong Buy-$46 and said, "We think EWTX offers a highly attractive risk/reward skew at current prices: Upcoming Phase 2 CIRRUS-HCM Part D results in 2H25 can meaningfully de-risk EDG-7500 in oHCM." $BMY $CYTK Raymond James added, "We think results from Parts B/C are encouraging (solid efficacy, minimal LVEF % impact), suggesting a path forward with potential to avoid a REMS; the possible a-fib signal should be manageable. The opportunity in nHCM is more difficult to de-risk, but completely out of the stock, in our view."
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 27 at 8:06 PM
$VKTX should have sold at its peak like $CYTK if they wanted a buyout. Cheering on both companies and there are reasons to be bullish… But you all need to realize this is an “if they’re bought” situation, not a WHEN .
3 · Reply
bagsOfCash
bagsOfCash Jul. 25 at 2:19 PM
$CYTK institutions are accumulating, I am doing the same
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 25 at 3:56 AM
$CYTK is getting back on my radar as a potential new obstructive HCM treatment ahead of its PDUFA… I turned down an opportunity from a friend to interview there a couple of years ago and I have tracked it closely since. 📈 FYI to my fellow $TNXP $KALV $NUVB investors… also to $SLS given it may get an accelerated approval 👀 Here weeeee go! 🚀
0 · Reply
RNASequencing
RNASequencing Jul. 24 at 5:36 PM
$ABVX sold within 12 months for 100-120 a share is a my guess but m and an always difficult to predict. Seems obvious, but so was $CYTK 🤷🏼‍♂️
0 · Reply
BNBComedian
BNBComedian Jul. 23 at 2:24 AM
$CYTK better molecules better data dumb CEO
0 · Reply
bhavn0081
bhavn0081 Jul. 21 at 6:33 PM
$CYTK | BULLISH | PT $75 Entering long position here at $55. Key catalysts ahead: PDUFA Dec 26, 2025: High chance of approval. PDUFA delay was procedural (REMS), not clinical. Competitive BEAST: Aficamten shows superior data to Camzyos ($BMY). nHCM Upside: ACACIA data in H1 '26 could nearly double the addressable market. FINANCES: Fully funded through launch. Clear path to $75. M&A potential is the cherry on top.
0 · Reply
The_Fudster
The_Fudster Jul. 18 at 1:35 PM
$CYTK honestly, Dougie over at SRPT is making blum look pretty damn good right now. Think market is finally waking up that this is a quality asset at a pretty good price nearing PDUFA
0 · Reply
Capitulation_0
Capitulation_0 Jul. 15 at 1:53 PM
$CYTK behaving unlike cytk...XBI down and this is up? Chart looks really good. I haven't said that for 2 years.
0 · Reply
peloswing
peloswing Jul. 14 at 3:17 PM
$CYTK Cytokinetics watch for a break of our trendline. Has been in this downtrend since April 2024. Will report earnings on July 31st as well (could be the catalyst it needs).
0 · Reply
Capitulation_0
Capitulation_0 Jul. 14 at 2:24 PM
$CYTK expecting early approval..
0 · Reply
Capitulation_0
Capitulation_0 Jul. 11 at 3:19 PM
$CYTK I don't remember the last time this was up when XBI was down.
0 · Reply
Capitulation_0
Capitulation_0 Jul. 11 at 12:54 PM
$CYTK $75 target.. When it gets approved it'll be north of this number.
0 · Reply
Capitulation_0
Capitulation_0 Jul. 11 at 12:52 PM
$CYTK started jogging towards PUDFA in Dec.
0 · Reply
Capitulation_0
Capitulation_0 Jul. 10 at 5:04 PM
$CYTK 7-8B BO... Let's go!
0 · Reply
Capitulation_0
Capitulation_0 Jul. 10 at 5:04 PM
$CYTK who would follow MRK to shore up patent cliff revenues...not too expensive for M&A
0 · Reply
Capitulation_0
Capitulation_0 Jul. 10 at 2:44 PM
$CYTK despite management, it could be the next BBIO
0 · Reply
SearchFor911
SearchFor911 Jul. 8 at 8:27 AM
$CYTK https://esc365.escardio.org/esc-congress/sessions/14380-hot-line-2
0 · Reply
SearchFor911
SearchFor911 Jul. 8 at 7:36 AM
$CYTK will present nHCM and aficamten vs metoprolol at ESC Congress 2025 in Madrid at 30th August
1 · Reply
McLarkin
McLarkin Jul. 3 at 11:32 AM
$CYTK feels like holding until year end, for approvals for folks to realise the value here, or news of some extra co-comercialisation deals like for Europe... expecting will ge good news... so sitting tight and bullish
0 · Reply